about
Natural selection of tumor variants in the generation of "tumor escape" phenotypesThe urgent need to recover MHC class I in cancers for effective immunotherapyAllogeneic tumor cell vaccines: the promise and limitations in clinical trialsMHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cellsA novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigensPrinciples of cancer therapy: oncogene and non-oncogene addictionHLA-G expression is an independent predictor for improved survival in high grade ovarian carcinomasMicroenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice.Quantification of HLA class I molecules on renal cell carcinoma using Edman degradationThe tumour suppressor Fhit positively regulates MHC class I expression on cancer cells.Recognition of tumors by the innate immune system and natural killer cells.The development of immunotherapies for non-small cell lung cancer.MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitroCytokines reinstate NK cell-mediated cancer immunosurveillance.Cytokine therapy reverses NK cell anergy in MHC-deficient tumorsReprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.Natural killer cells: role in local tumor growth and metastasisDendritic cell-based immunotherapy of malignant gliomas.Natural killer cells: can they be useful as adoptive immunotherapy for cancer?Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives.Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes.Immunosurveillance and immunotherapy of tumors by innate immune cells.The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survivalHuman leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy.Tumour infiltrating host cells and their significance for hyperthermia.MUC1 immunotherapy.Melanoma immunotherapy: historical precedents, recent successes and future prospects.NK cell self tolerance, responsiveness and missing self recognition.Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.HLA-E: a novel player for histocompatibility.Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype.Cancer immunotherapy: nanodelivery approaches for immune cell targeting and trackingThe delicate balance of melanoma immunotherapy.Cytokine therapy restores antitumor responses of NK cells rendered anergic in MHC I-deficient tumors.Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer.Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells.From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain.Rejection versus escape: the tumor MHC dilemma.The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture.Down-regulation of HLA-A mRNA in peripheral blood mononuclear cell of colorectal cancer.
P2860
Q24551158-00059903-03B0-4DA0-8F0B-C8550A0382E9Q26770165-89ED62DE-D863-46E6-B35C-F01F3062B993Q26852333-29FD93DA-1723-4EA1-B785-F0A5E903099FQ26866479-B3823A89-B8A8-4242-ABCF-EE70E782EC85Q27023313-ED5DF276-282C-4D84-A0BB-8E99C5B09481Q29616779-AECD9DC3-BE7F-4C16-AD40-88C0C13B04E4Q33758727-B1264581-6CA6-482C-9DB9-DDEAACD3652AQ33786788-826BAA3C-6374-4E2D-BA15-D51432E1C191Q33798689-6F072179-E46F-481B-B9ED-E7AD3E4CD9FBQ34208784-3C505A11-3E9C-42D6-9D19-3E91653684C6Q34496462-731C9B3A-4F33-4628-99CF-28315B5FB87CQ34560660-BE3D1ED0-5994-4997-9DF3-0D3078930EA3Q34615021-928AE6F4-56DC-4C09-90EB-DA2E0BD9386AQ35140082-306C9F0A-CD85-4ADE-A001-A47C5F12262DQ35140125-00AE0367-A53B-44FC-9DF0-869D5456FA29Q35799094-826B5D0F-04C3-4782-9BCB-667E8ED9753EQ35905953-A0E5AFBC-EB8E-497C-9C09-31C458962BF2Q35922426-B7D4C775-CE5D-49D8-874D-B4E7F9768D75Q36065944-9C18018A-3FA5-4C3A-B5EB-59E6855D667DQ36114649-BCADEC12-B5E0-4A04-97FF-C3036D0D290FQ36419244-10FC08AE-B833-4E55-B0F0-274347665B21Q36471212-17965E29-74A4-4A9C-8E2F-F1217EC2F9F6Q36614234-97F319DE-7F93-45C9-BE3C-491AD819E106Q37401538-3E5DDF69-3370-4EB8-82F3-85830E60C85CQ37730088-95696D76-2704-4149-B79F-2885F00E5E81Q37773241-1D14A3AD-963E-40FB-8F5A-15515A4D09E0Q38081911-C0E00A93-CC79-414F-9859-00E4F6498A00Q38196030-3B795588-3BB3-4BF1-8C35-4725D132F33BQ38198742-D6DCFC64-3C5C-4C40-9777-B2EF0A5CB2C1Q38268679-4EB9737F-31A5-43FD-BF9F-CF13B13101FAQ38282541-DE5BD9CD-FEDD-4D36-BC12-04A68EC45446Q38288055-522CD627-246F-47B1-8683-3824532FC493Q38288116-DE77706D-36C3-42C0-A8E2-197DA031C3DBQ38564238-4AEF21AE-5C25-4555-87D1-1299FA77FA90Q38590722-80876E95-BAA8-4040-ACD3-6FFE7E157F1CQ38806235-6495CDA3-6464-4E68-A75A-A6DF095E2A5BQ38951943-56A4E066-BA4D-48EA-9F16-DC285E0FF837Q39063943-831BC3FD-6240-4EF9-84B9-98AD96D8E4CFQ39164068-6C19A228-5AEA-41BD-9C96-1446CC47BCD5Q39704117-333B7EF6-C8C9-4C66-AED7-EDF8BC6D4D55
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
MHC antigens and tumor escape from immune surveillance.
@ast
MHC antigens and tumor escape from immune surveillance.
@en
MHC antigens and tumor escape from immune surveillance.
@nl
type
label
MHC antigens and tumor escape from immune surveillance.
@ast
MHC antigens and tumor escape from immune surveillance.
@en
MHC antigens and tumor escape from immune surveillance.
@nl
prefLabel
MHC antigens and tumor escape from immune surveillance.
@ast
MHC antigens and tumor escape from immune surveillance.
@en
MHC antigens and tumor escape from immune surveillance.
@nl
P1476
MHC antigens and tumor escape from immune surveillance.
@en
P2093
P304
P356
10.1016/S0065-230X(01)83005-0
P577
2001-01-01T00:00:00Z